Semarion Seed · $3M raised · (2022)

Semarion develops SemaCyte® microcarriers, which are ultra-miniaturised, barcoded micro-wells that enable adherent cells to become assay-ready reagents. This technology allows for the multiplexing of cell models in standard liquid handling workflows, facilitating faster, more scalable, and comparable cell-based experiments for in vitro drug discovery. Semarion serves teams looking to generate better data and accelerate drug discovery by removing bottlenecks in adherent cell screening.